Boulding Mark Elliott's Form 4 filing
PTC Therapeutics, Inc. (PTCT) · filed May 12, 2026
- Accession no.
- 0001578852-26-000014
- Filed
- May 12, 2026
- Trade date
- May 8, 2026
- Filing delay
- 4 days
- Rule 10b5-1 plan
- Checked
This filing lists 6 non-derivative transactions and 2 derivative transactions. Open-market sales total $279.6K. It was filed 4 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Boulding Mark ElliottCIK 0001578852 | Officer (EXEC. VP AND CLO) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| May 8, 2026 | Common Stock | MOption exerciseAcquired | +2,740 | $46.54 | +$127,519.6 | 107,952 | Direct | |
| May 8, 2026 | Common Stock | SSaleDisposed | −840 | $78.23F2 | −$65,713.2 | 107,112 | Direct | |
| May 8, 2026 | Common Stock | SSaleDisposed | −1,900 | $79.31F3 | −$150,689 | 105,212 | Direct | |
| May 8, 2026 | Common Stock | MOption exerciseAcquired | +800 | $46.54 | +$37,232 | 106,012 | Direct | |
| May 8, 2026 | Common Stock | SSaleDisposed | −200 | $78.00 | −$15,600 | 105,812 | Direct | |
| May 8, 2026 | Common Stock | SSaleDisposed | −600 | $79.28F4 | −$47,568 | 105,212 | Direct |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| May 8, 2026 | Common Stock | MOption exerciseDisposed | −2,740 | $0.00 | $0 | 42,260 | Direct | |
| May 8, 2026 | Common Stock | MOption exerciseDisposed | −800 | $0.00 | $0 | 41,460 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F2
This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $78.00 to $78.72 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.
Referenced by the price of 1 transaction in Table I.
- F3
This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $79.03 to $79.70 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.
Referenced by the price of 1 transaction in Table I.
- F4
This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $79.02 to $79.52 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.
Referenced by the price of 1 transaction in Table I.